Ayurvedic Strategies for Managing Non-alcoholic Fatty Liver Disease: A Holistic Approach
DOI:
https://doi.org/10.48165/IRJAY.2025.80509Keywords:
Hepatotoxic drug, Lifestyle changes,, Non-alcoholic fatty liver disease,, Samshodhana karmaAbstract
Metabolic disorders are now widespread even among seemingly healthy individuals. Non-alcoholic fatty liver disease (NAFLD) is one of them, NAFLD is a spectrum of liver disorders characterized by excessive fat accumulation in the liver, unrelated to alcohol consumption. It can progress from simple steatosis to non-alcoholic steatohepatitis, potentially leading to cirrhosis. NAFLD is closely linked to metabolic syndrome, obesity, and insulin resistance. NAFLD doesn’t directly align with any single Yakrit vikara (liver disorder) described in Ayurvedic classical texts.
Downloads
References
1. Kumar V, Abbas AK, Aster JC, Perkins JA. Robbins and cotran pathologic basis of disease. 10th ed. Philadelphia, PA: Elsevier; 2021. 2. Remya E. Non-alcoholic fatty liver disease-an Ayurvedic pragmatic approach with its management. Int J Ayurvedic Herbal Med. 2018;8(3):3230-6.
3. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M.
Global burden of NAFLD and NASH: Trends, predictions, risk factors and prevention. Hepatology. 2018;68(1):267-79.
4. Duseja A, Singh SP, Saraswat VA, Acharya SK, Chawla YK, Chowdhury S, Dhiman RK, Jayakumar RV, Madan K, Misra SP, Mishra H, Modi SK, Muruganathan A, Saboo B, Sahay R, Upadhyay R. Non-alcoholic fatty liver disease and metabolic syndrome-Position paper of the Indian National association for the study of the liver, endocrine society of India, Indian college of cardiology and Indian society of gastroenterology. J Clin Exp Hepatol. 2015;5(1):51-68. doi:10.1016/j.jceh.2015.02.006
5. Guo X, Yin X, Liu Z, Wang J. Non-alcoholic fatty liver disease (NAFLD) pathogenesis and natural products for prevention and treatment. Int J Mol Sci. 2022;23(24):15489.
6. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ. The diagnosis and management of non alcoholic fatty liver disease: Practice guideline by the American association for the study of liver diseases, American college of gastroenterology, and the American gastroenterological association. Hepatology. 2012;55(6):2005-23. doi:10.1002/hep.25762
7. Chandran A, Tiwari S. A scientific drug review on Punarnava Mandur. J Ayurveda Integr Med Sci. 2020;5(4):232-8.
8. Chandran A, Mahadevan L, Nisha MG, Pratap A. Non-alcoholic fatty liver disease - an Ayurvedic view. Int Ayurvedic Med J. 2021;9:2797-801.
9. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002;346(16):1221-31.
10. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, Natale S, Vanni E, Villanova N, Melchionda N, Rizzetto M. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003;37(4):917-23.
11. Romeo S, Kozlitina J, Xing C, Pertsemlidis A, Cox D, Pennacchio LA, Pennacchio LA, Boerwinkle E, Cohen JC, Hobbs HH. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet. 2008;40(12):1461-5.
12. Ryu S, Chang Y, Jung HS, Yun KE, Kwon MJ, Choi Y, Kim CW, Cho J, Suh BS, Cho YK, Chung EC, Shin H, Kim YS. Relationship of sitting time and physical activity with non-alcoholic fatty liver disease. J Hepatol. 2014;61(6):1228-35.
13. Boursier J, Mueller O, Barret M, Machado M, Fizanne L, Araujo-Perez F, Guy CD, Seed PC, Rawls JF, David LA, Hunault G, Oberti F, Calès P, Diehl AM. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota. Hepatology. 2016;63(3): 764-75.
14. Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism. 2016;65(8):1038-48.
15. Day CP, James OF. Steatohepatitis: A tale of two “hits”? Gastroenterology. 1998;114(4):842-5.
16. Panda AK, Bhuyan GC, Rao K, Binita P, Otta S, Parhi KK. Role of meda (adipocyte) in yakrit vikara (liver diseases) - ayurveda prospective. J Ayurveda Integr Med Sci. 2020;2:141-7.
17. Dash VB, Sharma RK. Principles of ayurvedic medicine - modern interpretation of tridosha imbalance in metabolic and hepatic conditions; 2021.
18. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Rinella M, Harrison SA, Brunt EM, Sanyal AJ. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328-57.
19. Hernaez R, Lazo M, Bonekamp S, Kamel I, Brancati FL, Guallar E, Clark JM. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: A meta-analysis.
56 Mishra, et al.: Ayurvedic Strategies for Managing Non-alcoholic Fatty Liver Disease 2025; 8(5):51-58
Hepatology. 2011;54(3):1082-90.
20. Szczepaniak LS, Nurenberg P, Leonard D, Browning JD, Reingold JS, Grundy S, Hobbs HH, Dobbins RL. Magnetic resonance spectroscopy to measure hepatic triglyceride content: Prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab. 2005;288(2):E462-8.
21. Pouwels S, Sakran N, Graham Y, Leal A, Pintar T, Yang W, Kassir R, Singhal R, Mahawar K, Ramnarain D. Non-alcoholic fatty liver disease (NAFLD): A review of pathophysiology, clinical management and effects of weight loss. BMC Endocr Disord. 2022;22:63. doi: 10.1186/s12902-022-00980-1
22. Bedossa P, Carrat F. Liver biopsy: The best, not the gold standard. J Hepatol. 2009;50(1):1-3.
23. Shastri A, editor. Sushruta samhita, uttara tantra. Varanasi: Chaukhamba Prakashan; 2015. p. 14.
24. Vagbhata A. Maatrashitiyam adhyayam (Sutra Sthan 8/20-22). In: Paradakara Vaidya BH, editor. Ashtanga hrdaya with sarvanga sundara by arunadatta and ayurveda rasayana by hemadri. 9th ed. Varanasi: Chaukhambha Orientalia Publications; 2005.
25. Khartode CP, Hambire DN, Namdev J, Shinde SV, Ingole SS. A comprehensive review and meta-analysis. Int J Hepatol Res. 2024;6(2):4-5. doi:10.33545/26646595.2024.v6.i2a.4
26. Sharma PV, editor. Dhanvantari nighantu. 3rd ed. Varanasi: Chaukhambha Orientalia; 2002. p. 69.
27. Singh V, Kapoor NK, Dhawan BN. Effect of picroliv on protein and nucleic acid synthesis. Indian J Exp Biol. 1992;30:68-9.
28. Lee HS, Yoo CB, Ku SK. Hypolipemic effect of water extracts of Picrorhiza kurrooa in high-fat diet-treated mice. Fitoterapia. 2006;77(7-8):579-84.
29. Al Zarzour RH, Ahmad M, Asmawi MZ, Kaur G, Saeed MAA, Al-Mansoub MA, Saghir SAM, Usman NS, Al-Dulaimi DW, Yam MF. Phyllanthus niruri standardized extract alleviates the progression of non-alcoholic fatty liver disease and decreases atherosclerotic risk in Sprague-Dawley rats. Nutrients. 2017;9(7):766.
30. Liu L, Wang B, Ma Y, Sun K, Wang P, Li M, Dong J, Qin M, Li M, Wei C, Tan Y, He J, Guo K, Yu XA. A review of Phyllanthus urinaria L. in the treatment of liver disease: Viral hepatitis, liver fibrosis/cirrhosis, and hepatocellular carcinoma. Front Pharmacol. 2024;15:1443667.
31. Jain R, Pandey S, Rishi A, Sharma A, Jain AK. Evaluation of hepatoprotective activity of Trikatu in CCl4-induced liver injury in albino rats. Int J Green Pharm. 2018;12(3):571-575.
32. Sharma S, Pandey S, Sharma P. Evaluation of antioxidant and hepatoprotective activity of Trikatu churna in ethanol-induced hepatotoxicity in rats. J Drug Deliv Ther. 2021;11(2):92-7.
33. Singh D, Chander R, Kapoor NK, Dhawan BN. Hepatoprotective activity of Apium graveolens and Hygrophila auriculata against paracetamol and thioacetamide intoxication in rats. Indian J Exp Biol. 1995;33:337-41.
34. Upadhyay S, Joshi B, Roy S. Hepatoprotective effect of daruharidra (Berberis aristata DC) in Wistar albino rats. Int J Ayurveda Pharm Chem. 2015;3(1):11-8.
35. Lamichhane R, Shrestha J. Study of hepatoprotective activity of polyherbal formulation on CCl4 induced liver damage in albino rats. J Sci Eng Res. 2018;5(5):145-53.
36. Mishra A, Rathi B, Pandey A, Kumar S, Singh R. Hepatoprotective activity of Bhumyamalaki (Phyllanthus niruri Linn.) against ethanol induced liver injury in albino rats. AYU. 2011;32(2):229-32.
37. Meena K, Bansal P. A study of hepatoprotective activity of Bhunimba (Andrographis paniculata) in CCl4 induced hepatotoxicity in albino rats. Int J Ayurvedic Med. 2012;3(1):36-41.
38. Jamwal R, Kumar N, Dogra R. Evaluation of hepatoprotective activity of Andrographis paniculata against paracetamol-induced
liver damage in albino rats. J Pharm Res Int. 2021;33(48B):191-9. 39. Trivedi NA, Rawal UM, Patel BP, Bhatt JD, Hemavathi KG. Hepatoprotective effect of Andrographis paniculata against hexachlorocyclohexane-induced liver damage in rats. Indian J Pharmacol. 2007;39(2):114-7.
40. Shukla S, Mehta A, Mehta P, Bajpai VK. Studies on anti inflammatory, antipyretic and analgesic properties of Caesalpinia bonducella F. seed oil in experimental animal models. Food Chem Toxicol. 2010;48(1):61-4.
41. Sharma A, Chandrakar S, Choudhury M, Raghuwanshi DK. Pharmacological evaluation of hepatoprotective activity of Boerhavia diffusa against CCl4-induced hepatotoxicity in albino rats. Int J Pharm Sci Rev Res. 2011;6(2):20-3.
42. Khan MR, Kihara M, Omoloso AD. Antimicrobial activity of Hygrophila auriculata. Fitoterapia. 2001;72(6):713-6.
43. Khosla P, Bhanwra S, Singh J, Seth S, Srivastava RK. A study of hypoglycaemic effects of Azadirachta indica (Neem) in normaland alloxan diabetic rabbits. Indian J Physiol Pharmacol. 2000;44(1):69-74.
44. Bandyopadhyay D, Biswas K, Bhattacharyya M, Reiter RJ, Banerjee RK. Melatonin protects against stress-induced gastric lesions by scavenging the hydroxyl radical. J Pineal Res. 2000;29(3): 143-51.
45. Khare CP. Indian medicinal plants: An illustrated dictionary. Berlin: Springer; 2007.
46. Tiwari R, Rana AC, Tiwari G, Srivastava B, Nema RK. Phytochemical and pharmacological screening of petroleum ether and ethanol extract of leaves of Cassia fistula Linn. J Glob Pharm Technol. 2009;1(1):13-8.
47. Singla R, Jaitak V. Shatavarin and diosgenin enriched extract of Asparagus racemosus modulates fatty acid oxidation and reduces insulin resistance in NAFLD. J Ethnopharmacol. 2021;264:113210.
48. Nariya M, Bhalodia N, Shukla VJ, Acharya RN. In vitro evaluation of antioxidant activity of Cordia dichotoma (Forst f.) bark. Ayu. 2011;32(4):532-6.
49. Kumari S, Yadav M, Singla RK. Polyherbal formulation: Phytochemical and hepatoprotective study. Indian J Pharm Sci. 2012;74(4):457-60.
50. Ghosh MN. Fundamentals of experimental pharmacology. 6th ed. Kolkata: Hilton and Co.; 2015. p. 153-60.
51. OECD. Guidelines for the testing of chemicals. Test No. 423: Acute oral toxicity - acute toxic class method. Paris: OECD Publishing; 2001.
52. Buege JA, Aust SD. Microsomal lipid peroxidation. Methods Enzymol. 1978;52:302-10.
53. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem. 1979;95(2):351-8.
54. Kakkar P, Das B, Viswanathan PN. A modified spectrophotometric assay of superoxide dismutase. Indian J Biochem Biophys. 1984;21(2):130-2.
55. Aebi H. Catalase in vitro. Methods Enzymol. 1984;105:121-6. 56. Moron MS, Depierre JW, Mannervik B. Levels of glutathione, glutathione reductase and glutathione S-transferase activities in rat lung and liver. Biochim Biophys Acta. 1979;582(1):67-78. 57. Reitman S, Frankel S. A colorimetric method for the determination of serum glutamic oxalacetic and glutamic pyruvic transaminases. Am J Clin Pathol. 1957;28(1):56-63.
58. King J. The hydrolases-acid and alkaline phosphatase. In: Practical clinical enzymology. London: Van Nostrand; 1965. p. 191-208. 59. Malloy HT, Evelyn KA. The determination of bilirubin with the
photoelectric colorimeter. J Biol Chem. 1937;119:481-90. 60. Trivedi RC, Rebar L, Berk JE. New enzymatic method for serum
Mishra, et al.: Ayurvedic Strategies for Managing Non-alcoholic Fatty Liver Disease 2025; 8(5):51-58 57
cholesterol estimation. Clin Chem. 1978;24:1008-9.
61. Fossati P, Prencipe L. Serum triglycerides determined colorimetrically with an enzyme that produces hydrogen peroxide. Clin Chem. 1982;28(10):2077-80.
62. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18(6):499-502.
63. Wilson PW, D’Agostino RB, Levy D, Belanger AM, Silbershatz H,
Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97(18):1837-47.
